Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Precigen, Inc. stock logo
PGEN
Precigen
$1.83
+4.0%
$1.51
$0.65
$2.17
$540.18M1.781.48 million shs1.80 million shs
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$1.10
$1.09
$0.26
$1.28
$116.26M1.61957,342 shsN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$6.85
+3.6%
$6.33
$4.95
$12.83
$489.36M0.94712,338 shs321,947 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$15.46
+1.2%
$10.37
$3.42
$17.00
$714.25M1.021.11 million shs2.31 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Precigen, Inc. stock logo
PGEN
Precigen
0.00%-3.83%+21.38%+28.47%+10.69%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00%0.00%0.00%0.00%0.00%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00%-2.36%+8.01%+10.72%-29.15%
Urogen Pharma stock logo
URGN
Urogen Pharma
0.00%+7.23%+4.23%+58.07%-3.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Precigen, Inc. stock logo
PGEN
Precigen
4.0526 of 5 stars
3.50.00.04.73.91.70.6
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.0002 of 5 stars
0.03.00.00.01.30.83.1
Urogen Pharma stock logo
URGN
Urogen Pharma
4.4314 of 5 stars
4.52.00.04.52.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Precigen, Inc. stock logo
PGEN
Precigen
3.00
Buy$6.00227.87% Upside
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00
N/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00
N/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.86112.53% Upside

Current Analyst Ratings Breakdown

Latest SCTL, URGN, PGEN, and SIGA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
7/7/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/16/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$50.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$16.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Buy$31.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $30.00
6/12/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
6/12/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/3/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Precigen, Inc. stock logo
PGEN
Precigen
$4.20M128.58N/AN/A$0.13 per share14.08
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$94.64M1.23N/AN/A$0.56 per share1.96
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$138.72M3.53$0.87 per share7.90$3.02 per share2.27
Urogen Pharma stock logo
URGN
Urogen Pharma
$90.40M7.90N/AN/A($0.21) per share-73.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Precigen, Inc. stock logo
PGEN
Precigen
-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
-$13.27M-$0.15N/AN/A-14.03%-23.82%-8.80%N/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$59.21M$0.6710.225.48N/A40.30%25.21%22.05%7/30/2025 (Estimated)
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)

Latest SCTL, URGN, PGEN, and SIGA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.14N/AN/AN/A$0.67 millionN/A
8/12/2025Q2 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.85N/AN/AN/A$23.06 millionN/A
5/14/2025Q1 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million
5/12/2025Q1 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million
5/8/2025Q1 2025
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A-$0.01N/A-$0.01N/A$7.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Precigen, Inc. stock logo
PGEN
Precigen
N/A
3.53
3.53
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.01
1.07
0.86
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
8.40
6.28
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
5.65
5.47

Institutional Ownership

CompanyInstitutional Ownership
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
87.15%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Precigen, Inc. stock logo
PGEN
Precigen
47.10%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
7.60%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
1.95%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Precigen, Inc. stock logo
PGEN
Precigen
190295.18 million156.15 millionOptionable
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
258105.69 million97.66 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.44 million70.05 millionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.20 million44.03 millionOptionable

Recent News About These Companies

Biotech lab
3 Bullish Biotech Stocks With Explosive Growth Trends (URGN)
...
Urogen Pharma's (URGN) Buy Rating Reiterated at HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Precigen stock logo

Precigen NASDAQ:PGEN

$1.83 +0.07 (+3.98%)
Closing price 04:00 PM Eastern
Extended Trading
$1.84 +0.00 (+0.27%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Societal CDMO stock logo

Societal CDMO NASDAQ:SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$6.85 +0.24 (+3.63%)
Closing price 04:00 PM Eastern
Extended Trading
$6.80 -0.05 (-0.73%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$15.46 +0.19 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$15.37 -0.09 (-0.61%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.